What changed: Thyroid cancer
Every dated change on the records linked to Thyroid cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 1
2025 · 2
2023 · 2
2022 · 3
- 2022ApprovalDonafenibDonafenib approved in China
Radioiodine-refractory differentiated thyroid cancer
- 2022Trial resultESTIMABL2ESTIMABL2 reported
3-year event-free 95.
- 2022MilestoneESTIMABL2ESTIMABL2: no radioiodine for low-risk disease; ASTRA adjuvant redifferentiation negative
A milestone in how this cancer is treated.
2021 · 1
May 2020 · 1
2020 · 4
- 2020ApprovalAnlotinibAnlotinib approved in China
Advanced medullary thyroid cancer
- 2020ApprovalSelpercatinibSelpercatinib approved in US
RET-fusion NSCLC and thyroid; RET-mutant MTC
- 2020MilestoneSelpercatinibSelpercatinib and pralsetinib: RET-selective inhibitors approved
A milestone in how this cancer is treated.
- 2020MilestoneSelpercatinibSelpercatinib approved
A milestone in how this cancer is treated.
2019 · 1
2018 · 2
- 2018Trial resultROAR (anaplastic thyroid cancer cohort)ROAR (anaplastic thyroid cancer cohort) reported
ORR 56%; median OS 15 months.
- 2018MilestoneROAR (anaplastic thyroid cancer cohort)Dabrafenib-trametinib approved for BRAF V600E anaplastic thyroid cancer (ROAR); larotrectinib tumour-agnostic
A milestone in how this cancer is treated.
2015 · 3
2014 · 3
- 2014ApprovalCabozantinibCabozantinib approved in EU
Cometriq for medullary thyroid cancer; 21 Mar 2014. Cabometyx (RCC) Sep 2016
- 2014ApprovalDabrafenibDabrafenib approved in US
With trametinib: BRAF V600E/K metastatic melanoma; later adjuvant melanoma, BRAF V600E NSCLC, anaplastic thyroid cancer, tumour-agnostic solid tumours and paediatric low-grade glioma
- 2014ApprovalTrametinibTrametinib approved in US
With dabrafenib: metastatic melanoma; later adjuvant melanoma, NSCLC, anaplastic thyroid cancer, tumour-agnostic BRAF V600E solid tumours, paediatric low-grade glioma
2013 · 3
- 2013ApprovalSorafenibSorafenib approved in US
Radioiodine-refractory differentiated thyroid cancer
- 2013Trial resultDECISIONDECISION reported
PFS 10.
- 2013MilestoneDECISIONSorafenib approved for RAI-refractory disease (DECISION); selumetinib redifferentiation proof of concept
A milestone in how this cancer is treated.
2012 · 3
April 2011 · 1
2011 · 2
2009 · 1
2003 · 1
2000 · 1
1998 · 1
1985 · 1
1951 · 1
1946 · 3
- 1946RegulatoryRadioactive iodine (I-131)Radioactive iodine (I-131): approval (US)
First therapeutic use in thyroid cancer (Seidlin); formal approval followed
- 1946MilestoneRadioactive iodine (I-131)First patient treated with radioactive iodine for metastatic thyroid cancer
Seidlin, Marinelli, and Oshry: the first theranostic.
- 1946MilestoneThyroid cancerRadioactive iodine: first theranostic
A milestone in how this cancer is treated.